<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538314</url>
  </required_header>
  <id_info>
    <org_study_id>UV1/hTERT-MM-103</org_study_id>
    <nct_id>NCT03538314</nct_id>
  </id_info>
  <brief_title>UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma</brief_title>
  <official_title>A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultimovacs ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultimovacs ASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and
      in combination with ipilimumab in malignant melanoma. This study will explore the safety,
      tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also
      receiving pembrolizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>UV1/GM-CSF</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>Up to week 29</time_frame>
    <description>Frequency and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Up to week 52</time_frame>
    <description>RECIST and irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of time from the start of treatment that patients are still alive.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UV1/GM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UV1/GM-CSF</intervention_name>
    <description>UV1 (300 microgram) GM-CSF (37.5 microgram)</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Stage IIIB, IIIC or IV melanoma

          2. Previously untreated and eligible for pembrolizumab treatment (prior treatment with
             BRAF and MEK inhibitors permitted) 3) Adequate blood, liver and kidney function 4)
             Consent to undergo tumor biopsies during the study

        Exclusion Criteria:

          1. Uveal or ocular malignant melanoma

          2. History of hematologic or primary solid tumor malignancy with the exception of
             patients in remission for at least 5 years, as judged by the investigator are allowed

          3. Prior systemic treatment for unresectable or metastatic melanoma. Exception: Prior
             treatment with BRAF and MEK inhibitors permitted. A washout period of at least
             3-half-lives (median terminal half-life) prior to the first dose of trial treatment
             must have elapsed.

          4. Prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, anti-PD-L2 agent or oncolytic
             virus.

          5. Known hypersensitivity to GM-CSF

          6. Women who are breastfeeding, pregnant or expect to be pregnant during the study
             through 6 months after the last dose

          7. Men who plan to become a father during the study through 4 months after the last dose
             of study medication

          8. Known history of, or any evidence of active, non-infectious pneumonitis

          9. History of cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John Wayne Cancer Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hunter Cole</last_name>
      <phone>310-449-5224</phone>
    </contact>
    <investigator>
      <last_name>Steven J O'Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Carver College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Smith</last_name>
      <phone>319-467-5830</phone>
    </contact>
    <investigator>
      <last_name>Mohammed M Milhem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Rex, RN</last_name>
      <phone>484-503-4152</phone>
      <email>robyn.rex@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Agarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Hunter</last_name>
      <phone>801-213-4299</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Voorhies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

